A meta‐analysis of XPC Lys939Gln polymorphism and melanoma susceptibility

Background It has been reported that polymorphisms of XPC Lys939Gln may affect the risk of melanom. However, the results have been inconsistent.We performed a comprehensive meta‐analysis to determine the association between XPC Lys939Gln polymorphism and melanoma susceptibility. Methods Based on comprehensive searches of the MEDLINE , EMBASE and ISI Web of knowledge, China National Knowledge Infrastructure ( CNKI ) and Wanfang Database, we identified eligible studies about the association between XPC Lys939Gln polymorphism and melanoma risk. Results A total of 4631 cases and 5111 controls in studies were included in this meta‐analysis. All studies were conducted in Caucasian populations. Allele model (Gln vs. Lys: P = 0.22; OR = 1.07, 95% CI = 0.96–1.18), and homozygous model (Gln/Gln vs. Lys/Lys: P = 0.66; OR = 1.03, 95% CI = 0.91–1.17) did not show increased risk of developing melanoma. Similarly, dominant model Gln/Gln and Gln/Lys vs. Lys/Lys: P = 0.07; OR = 1.17, 95% CI = 0.99–1.40) and recessive model (Gln/Gln vs. Gln/Lys and Lys/Lys: P = 0.67; OR = 1.03, 95% CI = 0.90–1.19) failed to show increased risk of developing melanoma. Conclusion Our pooled data suggest that there was no evidence for a major role of XPC Lys939Gln polymorphism in the pathogenesis of melanoma.